Gynecologic Cancer News

New Epigenetic Cervical Cancer Test Outperforms Pap and HPV Testing

New Epigenetic Cervical Cancer Test Outperforms Pap and HPV Testing

Epigenetic aberrations, as opposed to DNA mutations themselves, might play a more important role in the progression of many malignancies.

Lynparza OK'd as First-Line Maintenance of BRCA-Mutated Advanced Ovarian CA

Lynparza OK'd as First-Line Maintenance of BRCA-Mutated Advanced Ovarian CA

Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor is already approved to treat certain breast, epithelial ovarian, fallopian tube or primary peritoneal cancers based on an FDA-approved companion diagnostic.

Study Questions Benefits of Minimally Invasive Surgery for Early-Stage Cervical Cancer

Study Questions Benefits of Minimally Invasive Surgery for Early-Stage Cervical Cancer

New findings conflict with earlier retrospective studies and the general consensus supporting the use of minimally invasive surgery in early-stage cervical cancer.

Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer

Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer

Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

Patients in the real world setting were initiated at a lower dose and experienced fewer side effects than trial participants.

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.

USPSTF Updates Its Recommendations for Cervical Cancer Screening

USPSTF Updates Its Recommendations for Cervical Cancer Screening

The US Preventive Services Task Force conducted a review of trials and cohort studies to support an update of its cervical cancer screening recommendations for women ages 21 to 65 and older.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer

Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer

Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.

Could HPV Testing Take the Place of the Pap for Cervical Cancer Screening?

Could HPV Testing Take the Place of the Pap for Cervical Cancer Screening?

The confirmation of a positive HPV test appeared to be more predictive of a grade 2 or 3 cervical lesion than cytology screening alone.

Pembrolizumab FDA-Approved for the Treatment of Advanced Cervical Cancer

Pembrolizumab FDA-Approved for the Treatment of Advanced Cervical Cancer

Pembrolizumab is the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer.

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.

Ovarian Cancer Vaccine Shows Promise

Ovarian Cancer Vaccine Shows Promise

The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer

Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer

Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.

Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status

Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status

p53 mutational status may be a viable strategy upon which to base the course of therapy.

Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer

Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer

There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.

Antidepressants May Not Increase Ovarian Cancer Risk

Antidepressants May Not Increase Ovarian Cancer Risk

Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs